Hydroxocobalamin Rph Pharmaceuticals (Hydroxocobalamin Chloride)

Hydroxocobalamin serves as a cofactor for enzymes such as methionine synthase and methylmalonyl‑CoA mutase. By participating in these biochemical pathways, it supports DNA synthesis, red blood cell formation, and myelin production, thereby correcting the metabolic disturbances caused by B12 deficiency.

The dosage of hydroxocobalamin is determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of deficiency, and response to therapy. Only a qualified prescriber should set the appropriate dose and administration schedule.

Safety data for hydroxocobalamin in pregnancy and lactation are limited. It should be used only if clearly needed and after consultation with a healthcare provider, who will weigh the potential benefits against any possible risks to the mother and infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Hydroxocobalamin is a long‑acting cobalamin form that remains in the body longer than cyanocobalamin, allowing less frequent dosing. It is also the preferred form for treating cyanide poisoning. Both forms correct B12 deficiency, but hydroxocobalamin may offer advantages in patients needing sustained B12 levels.

Hydroxocobalamin for injection should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Hydroxocobalamin is administered by intramuscular injection, typically into the deltoid or gluteal muscle. The injection should be performed by a qualified healthcare professional using aseptic technique, following the dosage and schedule prescribed for the individual patient.

Serious risks include anaphylactic reactions, severe hypertension, thromboembolic events, and acute hemolysis. Patients should be monitored for signs of allergic response, sudden blood pressure changes, or unexplained bleeding, and medical attention should be sought immediately if such symptoms occur.

Hydroxocobalamin should be avoided in individuals with a known hypersensitivity to cobalamin or any component of the formulation. Caution is also advised for patients with severe renal impairment or those receiving treatments that may interact significantly, unless supervised by a healthcare professional.